Synergy CHC Corp (SNYR): Koefisien rega marang pendapatan

Simbol lan logo merek Synergy CHC Corp (SNYR)

Geopolitical instability is disrupting raw material logistics and reducing American purchasing power, which pressures the profitability of Synergy CHC Corp (SNYR). The estimated P/S on GURU.Markets contains a breaking point caused by severe pressure in the online segment and stagnation in the consumer cycle. However, the efficiency of D2C channels and IT infrastructure mitigate these risks. The value of 0.00 indicates the level of this metric.

SNYR Rasio rega marang pendapatan Synergy CHC Corporation (02.04.2025 - 03.10.2026)

Rincian metrik lan analitis perusahaan Synergy CHC Corp. (SNYR)

- rega saham lan konsensus proyeksi valuasi:
Analisis umum perusahaan:Synergy CHC Corp
Produk seri Synergy CHC

The outsourcing model of Synergy CHC Corp (SNYR) shifts production risks to external contractors, making revenue a key indicator of management efficiency. The fundamental P/S ratio reflects the market value of the business relative to its annual turnover, allowing for an assessment of the cost per unit of sales. This metric is calculated as the ratio of market capitalization to the company's total revenue. Extremely low values on this chart may signal a "value trap" and the risk of long-term capital stagnation.

Karo sapa Synergy CHC Corp saingan

HLN (Haleon) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue Inc KVUE|Verona Pharma Corp - Rasio rega marang pendapatan|MENS: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Rasio rega marang pendapatan|Perrigo Company PLC - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan alvotech.com|Multiplikator P/S Liquidia Technologies|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|ANIP: Rasio rega marang dodolan|Multiplikator P/S MNKD (MannKind Corp)|Koefisien rega marang pendapatan Amphastar (AMPH)|PCRX: Kapitalisasi marang pendapatan|SPRY - Multiplikator P/S|Theravance Biopharma, Inc. (TBPH) - Rasio rega marang pendapatan|AQST (Aquestive Therapeutics) - Rasio rega marang pendapatan|SCPH (scpharmaceuticals.com) - Multiplikator P/S|TECX: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EPRX (Eupraxia Pharmaceuticals)|Rasio kapitalisasi pasar marang pendapatan BHST|Invizyne Technologies - Multiplikator P/S|oramed.com (ORMP) - Kapitalisasi marang pendapatan|ENTX (enterabio.com) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan HYFT|ABVC (ABVC BioPharma, Inc) - Multiplikator P/S|Multiplikator P/S cumberlandpharma.com|Rasio rega marang pendapatan Quantum BioPharma (QNTM)|FibroGen (FGEN) - Multiplikator rega marang pendapatan|Multiplikator P/S TELO (telomirpharma.com)|RANI - Kapitalisasi marang pendapatan|RLYB: Kapitalisasi marang pendapatan|lexariabioscience.com (LEXX) - Kapitalisasi marang pendapatan|Pulmatrix Inc (PULM) - Rasio rega marang pendapatan|PTHL: Kapitalisasi marang volume dodolan|APM (Aptorum Group Ltd) - Multiplikator P/S|Lyra Therapeutics Inc (LYRA) - Koefisien rega marang pendapatan|Multiplikator P/S IBO|Kapitalisasi marang volume dodolan TNFA|cbdMD, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PRFX|Altamira Therapeutics Ltd. - Multiplikator P/S|LIPO: Rasio rega marang pendapatan|OPTN: Multiplikator P/S|Rasio rega marang dodolan PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - Multiplikator P/S|PTPI (Petros Pharmaceuticals Inc) - Kapitalisasi marang volume dodolan|Multiplikator P/S QLI|SLRN - Rega marang dodolan|Multiplikator P/S TFFP (TFF Pharmaceuticals, Inc)